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Abstract
Carcinoid heart disease is a rare but impactful sequelae for patients with
carcinoid syndrome, associated with a poor long-term prognosis (Ram, Yuan).
Patients with classic features of flushing, diarrhea, and bronchospasm require
attention and workup for carcinoid syndrome. Patients with florid carcinoid
syndrome have a 50% likelihood of cardiac involvement [5]. Carcinoid heart
disease occurs when large amounts of vasoactive substances reach the right
heart, cause endocardial injury, and resultant plaque is deposited at the
endocardial surface of the right sided heart valves, papillary muscles, and
chordae tendineae [5,11,12]. Symptoms vary depending on the affected
structures, but most often are consistent with right heart failure. Diagnosis can be
difficult and requires a high degree of clinical suspicion to obtain serologic
studies, imaging, and often right heart catheterization. Treatment requires a
multidisciplinary approach, involving medical and surgical management.
Appropriate treatment allows for improved quality of life and survival in these
cases [5]. Here we will discuss the case of a 74 year old gentleman with
carcinoid disease, with metastasis to the liver, and known carcinoid heart
disease, requiring tricuspid and pulmonic valve replacement.

Case Presentation
Patient is a 74 year old male with a past medical history of carcinoid disease with
metastasis to the liver, which he receives monthly Octreotide injections at Moffitt,
that presented to our hospital for an elective pulmonic valve and tricuspid valve
replacement on 11/4/1029 with our cardiovascular surgery team. The surgery had
a successful placement of a 27mm freestyle bio-prothesis PV and 31mm
bioprosthetic valve TV, without any complication.
He required multiple pressors after surgery including various intervals of
milrinone, levophed, epinephrine, and vasopressin while being on an octreotide
drip. He was initially sent to the ICU on the ventilator with epicardial leads and 2
chest tubes, which were eventually removed before discharge. He was
successfully extubated shortly after surgery on 11/4, but on 11/7 a rapid response
was called due to altered mentation, decreased responsiveness, and dyspnea,
and the patient was subsequently intubated again.

Carcinoid tumors are a rare entity, arising in about 1.2 to 2.1 per 100,000
individuals in the general population every year [1]. However carcinoid heart
disease only arises in about 50% of these individuals with about 20% of these
individuals initially presenting due to cardiac complaints [2,3]. Carcinoid tumors
most commonly arise from the gastrointestinal tract, specifically at either the
midgut and occasionally also arise from the bronchopulmonary system.

Carcinoid tumors classically arise from the midgut which includes the jejunum,
ileum, appendix and ascending colon. However on rare occasions it can arise
from the hindgut which includes the transverse, descending colon, sigmoid colon,
rectum and genitourinary system. Approximately only 11% of carcinoid tumors
arise from the colon [1]. Carcinoid tumors of the colon only represent 1% of
colonic neoplasms [1]. Patients with colonic carcinoid tumors at diagnosis usually
have local nodal or distant metastases with an overall 5 year survival rate of
25%-41% [6].

Gastrointestinal neuroendocrine tumors, formerly known as carcinoid tumors, are
rare (incidence of 5 per 100,000 persons/year) and derived from the
neuroendocrine producing cells of the gastrointestinal tract.
Despite most commonly originating from the bronchus, jejenoileum and the
rectum, GI-NETs can arise from any part of the GI tract. Typically, patients do not
present with the classical findings of intermittent flushing, intestinal hypermotility
resulting in diarrhea and bronchospasm [7].
Carcinoid Heart Disease is a rare manifestation of the carcinoid syndrome
thought to be a result of the action of the many vasoactive substances produced
and released by the NETs. These substances result in the deposition of plaque
on the endocardial surfaces of the cardiac chambers as well as onto the valve
leaflets, chordae tendinae and papillary muscles.
In most cases, this plaque deposition occurs on the right side of the heart and
may result in the simultaneous development of tricuspid and pulmonic valve
disease which when occurring simultaneously can be considered as
pathognomonic of carcinoid heart disease.
The mainstay of treatment for carcinoid heart disease is valve replacement of the
tricuspid and pulmonic valves. Indications for valve replacement for a patient with
carcinoid heart disease and associated valvular involvement do not differ from
standard indications which include impaired exercise tolerance and fatigue, as
well as a decline in ventricular function. Valve replacement surgery appears to
improve survival in these patients. Surgical resection of cardiac metastases can
be done at the time of valve surgery. Prior to valve surgery medical therapy
should be optimized with somatostatin-analogs however alone, they do not
reverse valvular disease or valvular lesions [8,9,10].

Introduction

Once there is cardiac involvement it is associated with a poor long term
prognosis with an estimated 3 year survival rate of only 31% [4,5]. The most
commonly affected areas of the heart include the pulmonic valve and the
tricuspid valve. The left side of the heart is usually not affected unless there is a
patent foramen ovale or there are very high levels of vasoactive substances
which include: serotonin, histamine, bradykinin, tachykinins, prostaglandins and
5-hydroxytryptophan which overwhelm the pulmonary arterial circulation.

Discussion

Conclusion

Figure A showing Tricuspid Valve Carcinoid Heart disease, Figure B showing
Pulmonic Valve Carcinoid Heart disease. Figure C shows florid myofibroblastic
cell proliferation and Figure D shows myxoid stroma with myofibroblastic cell
proliferation [13].
He was placed on epinephrine and vasopressin at that time and underwent an
emergent TTE, which wasn’t adequate so a TEE was done by cardiology. TEE
showed an LVEF 55-60%, normal RV cavity size/function, mild-moderate AI, mild
MR, tricial TR, normal PVR, no intracardiac shunt on the bubble study, and well
seated bioprothetic valves. A weaning trial was performed and he was extubated
on 11/9/2019. His hospital course was also complicated by a stent exchange
from extrinsic compression of the carcinoid tumor which he has changed every 3
months and was started on Rocephin then Omnicef for an associated UTI. He
also developed new onset atrial flutter which resolved with amiodarone, and was
started on Eliquis.
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Carcinoid heart disease is a rare cause of right heart failure. Carcinoid heart
disease can occur in nearly 50% of patients with carcinoid syndrome [5]. Key
diagnostic factors include 24-hour urinary excretion of 5-HIAA, and TEE [5,11].
Medical and surgical treatment can significantly improve overall quality of life and
long-term survival [5]. Valve replacement surgery is currently the gold standard
treatment for symptomatic carcinoid valve disease [11]. Results of ongoing clinical
trials will be important to achieve further improvements in early diagnosis, medical
management, and surgical management, including alternative options for patients
who are high-risk for interventions.
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